Company
Telix
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
2
2 still marketed
Novel approvals
1
Approvals since 2021
3
Originals and new uses
Phase 3 trials
6
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)Pivotal-lookingRecruiting
Telix Pharmaceuticals (Innovations) Pty LimitedIndustry
NCT06520345 · 520 participants (planned) · Start Jul 26, 2024 · Primary completion Dec 2027
Drug: 177Lu-TLX591; Enzalutamide and 2 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Orange, California; Miami, Florida; Glen Burnie, Maryland · 33 sites in all
- 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP StudyPivotal-lookingRecruiting
Telix Pharmaceuticals (Innovations) Pty LimitedIndustry
NCT06750419 · 82 participants (planned) · Start Nov 6, 2024 · Primary completion Jun 30, 2026
Drug: 89Zr-TLX250 PET/CT · For: Clear Cell Renal Cell Carcinoma
Sites: Beijing, China; Hangzhou, China; Hubei, China · 8 sites in all
Marketed drugs (2)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.